Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of SIBP's MMR Vaccine Compared to GSK MMR Vaccine in Children, 9-11 Months of Age

NCT06399003 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.

NCT NCT06399003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of SIBP's MMR Vaccine Compared to GSK MMR Vaccine in Children, 9-11 Months of Age
Lead sponsor
Shanghai Institute Of Biological Products
Phase
Phase 3
Overall status
Completed
Start date
June 28, 2024
Completion date
March 10, 2025
Enrollment
1,200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

measles-mumps-rubella